These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 38705935

  • 1. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
    Ligumsky H, Amir S, Arbel Rubinstein T, Guion K, Scherf T, Karasik A, Wolf I, Rubinek T.
    Med Oncol; 2024 May 06; 41(6):138. PubMed ID: 38705935
    [Abstract] [Full Text] [Related]

  • 2. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 06; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

  • 3. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
    Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL.
    Peptides; 2013 Jan 06; 39():71-9. PubMed ID: 23116613
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
    Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, Sun J.
    Exp Clin Endocrinol Diabetes; 2017 Feb 06; 125(2):91-97. PubMed ID: 28008585
    [Abstract] [Full Text] [Related]

  • 5. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.
    Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, Beguinot F, Sesti G, Miele C, Folli F.
    J Transl Med; 2016 Jul 30; 14(1):229. PubMed ID: 27473212
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
    Yang S, Lin C, Zhuo X, Wang J, Rao S, Xu W, Cheng Y, Yang L.
    Am J Physiol Endocrinol Metab; 2020 Dec 01; 319(6):E1019-E1030. PubMed ID: 32985256
    [Abstract] [Full Text] [Related]

  • 7. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.
    Lee MY, Chen WC, Hsu WH, Chen SC, Lee JC.
    Int J Mol Sci; 2019 Sep 14; 20(18):. PubMed ID: 31540136
    [Abstract] [Full Text] [Related]

  • 8. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
    Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y.
    Atherosclerosis; 2017 Jun 14; 261():44-51. PubMed ID: 28445811
    [Abstract] [Full Text] [Related]

  • 9. Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.
    Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM.
    Cell Physiol Biochem; 2014 Jun 14; 33(2):423-32. PubMed ID: 24556697
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR, Monnier L, Bolli GB.
    Diabetes Metab; 2013 Dec 14; 39(6):485-96. PubMed ID: 24156868
    [Abstract] [Full Text] [Related]

  • 11. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.
    Wei R, Ma S, Wang C, Ke J, Yang J, Li W, Liu Y, Hou W, Feng X, Wang G, Hong T.
    Am J Physiol Endocrinol Metab; 2016 Jun 01; 310(11):E947-57. PubMed ID: 27072494
    [Abstract] [Full Text] [Related]

  • 12. Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells.
    Li Z, Ni CL, Yao Z, Chen LM, Niu WY.
    Metabolism; 2014 Aug 01; 63(8):1022-30. PubMed ID: 24972503
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism.
    Krasner NM, Ido Y, Ruderman NB, Cacicedo JM.
    PLoS One; 2014 Aug 01; 9(5):e97554. PubMed ID: 24835252
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
    Koehler JA, Kain T, Drucker DJ.
    Endocrinology; 2011 Sep 01; 152(9):3362-72. PubMed ID: 21771884
    [Abstract] [Full Text] [Related]

  • 15. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
    Miao X, Gu Z, Liu Y, Jin M, Lu Y, Gong Y, Li L, Li C.
    Peptides; 2018 Feb 01; 100():127-139. PubMed ID: 28712893
    [Abstract] [Full Text] [Related]

  • 16. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
    Kappe C, Zhang Q, Holst JJ, Nyström T, Sjöholm A.
    Am J Physiol Cell Physiol; 2013 Nov 15; 305(10):C1041-9. PubMed ID: 23986202
    [Abstract] [Full Text] [Related]

  • 17. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD, McAnally D, Ayala JE, Burmeister MA, Morfa C, Smith L, Ayala JE.
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct 01; 315(4):R595-R608. PubMed ID: 29949410
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
    Wang J, Fan S, Xiong Q, Niu Y, Zhang X, Qin J, Shi Y, Zhang L.
    Acta Biochim Biophys Sin (Shanghai); 2021 Aug 31; 53(9):1189-1197. PubMed ID: 34357376
    [Abstract] [Full Text] [Related]

  • 19. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
    Burmeister MA, Ayala J, Drucker DJ, Ayala JE.
    Am J Physiol Endocrinol Metab; 2013 Apr 01; 304(7):E677-85. PubMed ID: 23341495
    [Abstract] [Full Text] [Related]

  • 20. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
    Zhou Y, He X, Chen Y, Huang Y, Wu L, He J.
    Biochem Biophys Res Commun; 2013 Apr 01; 468(1-2):394-9. PubMed ID: 26519882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.